JP Morgan has upgraded Penumbra Inc (PEN) to Overweight from Neutral as of December 17, 2025. This move underscores a more favorable outlook on the company's prospects, suggesting improved fundamentals or better-than-expected business performance.
Penumbra, headquartered in Alameda, California, is a leading thrombectomy company that designs, develops, and markets innovative medical products. The firm specializes in removing blood clots through its broad portfolio, which includes computer-assisted vacuum thrombectomy (CAVT). It primarily serves healthcare providers in the U.S., Europe, Canada, and Australia.
As of December 16, 2025, Penumbra's market capitalization stands at $12.2 billion, with a price-to-earnings ratio of 74.26 and earnings per share of 4.14. The company is set to report its upcoming earnings on July 27, 2026, with an estimated EPS of $1.21 and revenue of $391.3 million.
Analyst ratings, such as this upgrade, offer insights based on extensive research and financial models. However, these assessments should be considered alongside other factors, including company fundamentals and market dynamics, rather than being the sole basis for investment decisions. Analyst opinions can also evolve as new information becomes available, leading to varying perspectives on the same company.
In the most recent analyst consensus as of December 1, 2025, Penumbra holds a consensus rating of Buy from a total of 24 analysts, with 8 rating it as Strong Buy, 12 as Buy, and 4 as Hold.